Lopes Marlene Almeida, Abrahim Bárbara Azevedo, Cabral Lucio Mendes, Rodrigues Carlos Rangel, Seiça Raquel Maria Fino, de Baptista Veiga Francisco José, Ribeiro António José
Centre for Pharmaceutical Sciences, Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, Coimbra, Portugal.
Centre for Pharmaceutical Sciences, Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, Coimbra, Portugal; Department of Pharmaceutics, Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Nanomedicine. 2014 Aug;10(6):1139-51. doi: 10.1016/j.nano.2014.02.014. Epub 2014 Mar 12.
Nanodelivery systems have been extensively studied as a strategy for the effective treatment of type 1 diabetes in animal models. Nanoparticle formulations have been shown to contribute to increased intestinal absorption of insulin according to established pathways. It is important to determine whether intestinal absorption of the hormone, specifically occurs through a privileged pathway that is favored because of particular properties of the nanoparticles. Confocal fluorescence microscopy has revealed that nanoparticles-based oral insulin delivery in intestinal tissues causes their accumulation in Peyer's patches. To quantify the preponderance of M cells involved in the overall absorption of insulin in the intestine, in vitro and in vivo results of insulin-loaded nanoparticles were analyzed and criticized based on the utilized method and whether it has translational impact for the treatment of diabetes in humans. The degree of insulin nanoparticles uptake will be interpreted for its effectiveness in the prevention/treatment of other pathologies.
This study investigates nano-formulation based insulin delivery through the oral route, with particular attention to their accumulation in Peyer patches and the role of M-cells in their absorption. While oral delivery of insulin would be an important step from the standpoint of convenience, accurate dosing and issues of potential toxicity need to be considered before clinical translation of this method.
纳米递送系统作为一种在动物模型中有效治疗1型糖尿病的策略已得到广泛研究。根据既定途径,纳米颗粒制剂已被证明有助于提高胰岛素的肠道吸收。确定激素的肠道吸收是否特别是通过因纳米颗粒的特殊性质而受到青睐的特权途径发生很重要。共聚焦荧光显微镜显示,基于纳米颗粒的口服胰岛素递送在肠道组织中会导致其在派尔集合淋巴结中积累。为了量化参与肠道胰岛素整体吸收的M细胞的优势,基于所使用的方法以及它对人类糖尿病治疗是否具有转化影响,对负载胰岛素纳米颗粒的体外和体内结果进行了分析和评判。胰岛素纳米颗粒的摄取程度将根据其在预防/治疗其他疾病中的有效性进行解读。
本研究调查了基于纳米制剂的胰岛素口服递送,特别关注其在派尔集合淋巴结中的积累以及M细胞在其吸收中的作用。虽然从便利性的角度来看,胰岛素的口服递送将是重要的一步,但在将该方法临床转化之前,需要考虑准确给药和潜在毒性问题。